6OP Stock Overview
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
OSE Immunotherapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.96 |
| 52 Week High | €10.68 |
| 52 Week Low | €3.15 |
| Beta | 0.83 |
| 1 Month Change | 9.43% |
| 3 Month Change | -19.35% |
| 1 Year Change | 114.81% |
| 3 Year Change | 4.04% |
| 5 Year Change | 104.71% |
| Change since IPO | -30.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6OP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.6% | -12.3% | -0.6% |
| 1Y | 114.8% | -15.3% | 14.8% |
Return vs Industry: 6OP exceeded the German Biotechs industry which returned -15.3% over the past year.
Return vs Market: 6OP exceeded the German Market which returned 14.8% over the past year.
Price Volatility
| 6OP volatility | |
|---|---|
| 6OP Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 6OP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6OP's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 52 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
| 6OP fundamental statistics | |
|---|---|
| Market cap | €157.05m |
| Earnings (TTM) | €46.03m |
| Revenue (TTM) | €83.44m |
3.4x
P/E Ratio1.9x
P/S RatioIs 6OP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6OP income statement (TTM) | |
|---|---|
| Revenue | €83.44m |
| Cost of Revenue | €0 |
| Gross Profit | €83.44m |
| Other Expenses | €37.41m |
| Earnings | €46.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | 55.17% |
| Debt/Equity Ratio | 49.6% |
How did 6OP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 21:56 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OSE Immunotherapeutics SA is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| David Seynnaeve | Degroof Petercam |
| Laura Roba | Degroof Petercam |